

Dermavant Sciences: a strong foundation to propel into the future

2015

September
Dermavant Sciences was founded



2018

March
David Rubenstein, MD, PhD, appointed Chief Scientific Officer




Christopher Van Tuyl, Esq, appointed General Counsel



July
Purchased rights to tapinarof, an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA) for the treatment of plaque psoriasis and atopic dermatitis




September
Began preparations for Phase 3 PSOARING clinical program for tapinarof in plaque psoriasis



October
Presented new Phase 2b tapinarof data on patient-reported outcomes for plaque psoriasis and atopic dermatitis at the Fall Clinical Dermatology Conference



November
Todd Zavodnick appointed Chief Executive Officer



2019


January
Philip M. Brown, MD, JD, appointed Chief Medical Officer




March
Presented Phase 2b secondary efficacy data of tapinarof in plaque psoriasis and Phase 2b secondary outcomes of tapinarof in atopic dermatitis at the American Academy of Dermatology Annual Meeting



Announced plan to initiate Phase 3 PSOARING clinical program for tapinarof



United States Patent and Trademark Office (USPTO) issued a formulation patent for tapinarof, expiring in 2036



June
Dosed first patient in Phase 3 PSOARING clinical trial program for tapinarof in plaque psoriasis




2020

January
Chris Chapman appointed Chief Commercial Officer




Signed exclusive license agreement with Japan Tobacco Inc. for development and commercialization of tapinarof in Japan



April
Completed patient enrollment for two identical Phase 3 clinical trials, PSOARING 1 and PSOARING 2, evaluating tapinarof in plaque psoriasis



May
Efficacy and patient-reported outcomes data from Phase 2b study evaluating tapinarof in plaque psoriasis was published in the *Journal of the American Academy of Dermatology (JAAD)*



June
Completed patient enrollment for PSOARING 3, a long-term safety study of tapinarof in adults with plaque psoriasis



Efficacy and patient-reported outcomes data from Phase 2b study evaluating tapinarof in atopic dermatitis was published in the *Journal of the American Academy of Dermatology (JAAD)*



August
Announced new data results from PSOARING 1 and PSOARING 2 evaluating tapinarof in plaque psoriasis



October
Presented efficacy and safety data from Phase 3 PSOARING clinical trial program evaluating tapinarof at the Fall Clinical Dermatology and European Academy of Dermatology and Venereology Congress




November
Fortune named Dermavant one of the "100 Best Small and Medium Companies to Work For"




2021

January
Presented new tapinarof data in plaque psoriasis from Phase 3 PSOARING clinical trial program at Maui Derm for Dermatologists




February
Announced new safety and efficacy data in plaque psoriasis from a planned interim analysis of PSOARING 3




March
Fortune named Dermavant one of the "Best Workplaces in Health Care & Biopharma," the company's second recognition in a row by the outlet




Presented interim analysis of PSOARING 3 evaluating tapinarof in plaque psoriasis at the Innovations in Dermatology Conference




April
Presented secondary efficacy and patient-reported outcomes data from PSOARING 1 and PSOARING 2 evaluating tapinarof in plaque psoriasis at the American Academy of Dermatology Virtual Meeting Experience




May
Michael Swartzburg appointed Chief Financial Officer



New Drug Application submitted to the US FDA for tapinarof for the treatment of plaque psoriasis in adult patients



June
Announced \$200 million of funding from partners including NovaQuest and Marathon



August
US FDA accepted the New Drug Application for tapinarof for the treatment of plaque psoriasis in adult patients



Future

With **150+ YEARS** of combined dermatology expertise from the Dermavant leadership team working towards our goal of transforming lives, the future at Dermavant is bright.

WE ARE EXCITED FOR YOU TO SEE WHAT'S NEXT!

